Maravai Lifesciences (MRVI) said late Thursday it has agreed to buy Officinae Bio's DNA and RNA business.
This acquisition will support Maravai Lifesciences and its TriLink BioTechnologies unit's customers in developing new nucleic acid-based therapies, Maravai Bio said.
Financial terms were not disclosed for the deal, which is slated to be completed early next year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments